Awakening of Small Nucleic Acid Drugs: Will 2024 Become a Landmark Year?

2024 holds promising prospects for small nucleic acid drugs, marking a potential awakening in this field. Recent collaborations and advancements in the development of innovative therapies have sparked renewed interest and investment. This article explores the latest breakthroughs and their implications for the future of small nucleic acid drugs.

In the pursuit of addressing the vast chronic disease market, the field of small nucleic acid drugs has achieved significant milestones at the beginning of 2024. One notable development is the partnership between RiboBio and Boehringer Ingelheim, focusing on the treatment of non-alcoholic fatty liver disease associated with metabolic disorders. The collaboration involves substantial financial investments, including milestone payments for clinical research, drug registration, commercial success, and sales royalties. With a transaction value exceeding $2 billion, this announcement has reignited enthusiasm for small nucleic acid drugs.

Another noteworthy collaboration is between Argo Biopharma and Novartis. Under the agreement, Novartis gains exclusive rights for a cardiovascular project in phase 1/2a clinical trials in the Greater China region, as well as global rights for another cardiovascular project in phase 1. Additionally, Novartis has the option to choose up to two other cardiovascular projects. Argo Biopharma receives a substantial upfront payment of $185 million, with the potential for total collaboration worth up to $4.165 billion. These partnerships demonstrate the growing significance of small nucleic acid drugs in the pharmaceutical industry.

RiboBio, established in 2007, specializes in the development of RNA interference (RNAi) therapeutics and currently has eight small nucleic acid drugs in clinical trials. Their pipeline encompasses chronic diseases, tumors, inflammation, and ophthalmology, with five drugs utilizing the proprietary RIBO-GalSTARTM technology platform based on N-acetylgalactosamine (GalNAc), a commonly used ligand system for liver targeting. Notably, RBD1016, targeting hepatitis B and hepatitis C, has entered phase 2 and phase 1 clinical trials worldwide, respectively. Additionally, RiboBio is developing RBD1007, an siRNA drug targeting Caspases 2 for optic nerve protection, which is currently in phase 3 clinical trials for non-arteritic anterior ischemic optic neuropathy (NAION). These advancements highlight the potential of small nucleic acid drugs in the field of liver diseases and ophthalmology.

Argo Biopharma, founded in April 2021, focuses on siRNA drug development and has established multiple technology platforms and a rich pipeline within less than three years. Their pipeline covers cardiovascular diseases, rare diseases, viral infections, metabolic diseases, and central nervous system disorders. Notably, their cardiovascular projects, BW-01 and BW-02, have entered clinical stages, with high prospects of being core products under the collaboration with Novartis. BW-01 targets lipid disorders, while BW-02 focuses on hypertension. The company's progress exemplifies the potential of small nucleic acid drugs in addressing various therapeutic areas.

Advantages of Small Nucleic Acid Drugs:
Small nucleic acid drugs, comprising mRNA and oligonucleotide drugs, offer several advantages over traditional and biological drugs. Their ability to target nearly all genetic components within cells, including previously undruggable targets, expands the range of druggable targets, including proteins and non-coding transcripts and genes. The development process for RNA drugs is relatively faster once the chemical structure of the RNA and its delivery method into the body are established. Moreover, modified RNA molecules have enhanced stability, enabling prolonged therapeutic effects, thereby reducing the dosing frequency. The cost of developing small nucleic acid drugs can be significantly lower once the chemical nature of RNA and its delivery systems are optimized, making them a viable option for treating rare diseases. Furthermore, compared to gene therapy, small nucleic acid drugs carry lower risks of genetic toxicity, providing a safer alternative. Due to their small size, these drugs offer multiple targets, a wide therapeutic window, and extended half-lives.

The year 2024 holds immense potential for small nucleic acid drugs, with significant collaborations and advancements paving the way for innovative therapies. The partnerships between RiboBio and Boehringer Ingelheim, as well as Argo Biopharma and Novartis, showcase the growing interest and investment in this field. The advantages of small nucleic acid drugs, such as their ability to target previously undruggable genetic components, faster development timelines, prolonged therapeutic effects, and reduced toxicity risks, make them a promising avenue for addressing various diseases. As we embark on this awakening year, the future of small nucleic acid drugs appears brighter than ever.